SPRC - Scisparc Ltd logo

Scisparc Ltd

SPRC

SciSparc Ltd. develops cannabinoid-based pharmaceuticals targeting central nervous system disorders. Its key products include SCI-110 for Tourette syndrome and Alzheimer's, SCI-210 for autism, and CannAmide for pain relief, along with hemp seed oil products.

⚕️ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago →$0today

Score Overview

1 Year
Score
Net Growth-44.10%
Net TrendShrank
Net Income Consistency—
Rev Growth33.18%
Rev TrendGrew
Revenue Consistency—
5 Years
Score2.7
Net Growth-202.53%
Net Trend20%
Net Income Consistency—
Rev Growth6.64%
Rev Trend60%
Revenue Consistency—
All Time
Score
Net Growth-202.53%
Net Trend20%
Net Income Consistency
Rev Growth6.64%
Rev Trend60%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Scisparc Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. SPRC does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 1.20—
1 Year2025-10-22
$ 34.29-96.50%
5 Years2021-10-22
$ 27.76K-100.00%
All Time2021-08-30
$ 22.11K-99.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1M-$ 17M
2025$ 856K-$ 12M$ 4M
2024$ 1M-$ 6M$ 2M
2023$ 2M-$ 5M$ 5M
2022$ 1M-$ 2M$ 3M
IPO2021$ 1M-$ 5M$ 6M
SPRC - Scisparc Ltd logo

Scisparc Ltd fundamental performance

Between 2021 and 2025, revenue declined from $ 1M to $ 856K and net income went from -$ 5M to -$ 12M. Revenue increased in 60% of the years measured; net income in 20%.

Scisparc Ltd currently holds a 5-year HDB Score of 2.7 out of 10. How the HDB Score is calculated.

Membership

Explore SPRC with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies